PTC Therapeutics (NASDAQ:PTCT) VP Sells $133,816.05 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $76.95, for a total transaction of $133,816.05. Following the completion of the transaction, the vice president directly owned 119,162 shares in the company, valued at $9,169,515.90. This trade represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Mark Elliott Boulding also recently made the following trade(s):

• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.44, for a total value of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.55, for a total value of $171,196.30.
• On Monday, November 17th, Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.99, for a total value of $213,683.88.

PTC Therapeutics Stock Performance

Shares of PTC Therapeutics stock traded down $0.39 during trading on Thursday, reaching $76.85. 1,625,361 shares of the company’s stock were exchanged, compared to its average volume of 1,684,365. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The company has a market cap of $6.17 billion, a P/E ratio of 8.98 and a beta of 0.49. The firm’s 50-day moving average price is $76.26 and its 200 day moving average price is $62.43.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The firm had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. During the same quarter in the previous year, the business posted ($1.39) earnings per share. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. As a group, equities research analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
• Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
• Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
• Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

Institutional Investors Weigh In On PTC Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. acquired a new stake in shares of PTC Therapeutics in the third quarter valued at about $97,252,000. Hood River Capital Management LLC boosted its holdings in PTC Therapeutics by 654.4% in the second quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock valued at $31,087,000 after acquiring an additional 552,130 shares during the last quarter. State Street Corp increased its position in PTC Therapeutics by 22.1% during the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock valued at $146,347,000 after purchasing an additional 541,558 shares during the period. Palo Alto Investors LP raised its holdings in PTC Therapeutics by 112.2% during the 3rd quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock worth $52,939,000 after purchasing an additional 456,144 shares during the last quarter. Finally, Man Group plc lifted its position in shares of PTC Therapeutics by 157.4% in the 2nd quarter. Man Group plc now owns 671,513 shares of the biopharmaceutical company’s stock worth $32,797,000 after purchasing an additional 410,653 shares during the period.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Citigroup upped their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Barclays boosted their target price on shares of PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Cowen reissued a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $90.00 target price on shares of PTC Therapeutics in a report on Thursday. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, PTC Therapeutics has a consensus rating of “Hold” and a consensus price target of $77.27.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.